SAFC today launched the first of its new offering of zinc finger nuclease (ZFN) modified CHO cell lines for use in production of biological drugs. The CHOZN cell lines have been designed to allow customers to reach the market faster and more cost effectively by reducing timelines in early-stage drug development. The features embodied in the lines should appeal to organizations trying to build a robust and comprehensive monoclonal antibody or therapeutic protein platform.
The first cell line to be introduced is the CHOZN DHFR-/- CHO line. The line was developed with the use of the CompoZn ZFM mediated knock out of the DHFR gene locus in a well-documented CHO-K1 host. The new line allows process development scientists to use any common DHFR expression system for the selection and amplification of their gene of interest in the CHO-K1 background.
SAFC is planning to introduce a CHOZN GS -/- CHO line next followed by a complete platform system based on the CHOZN GS -/- cell line matched to chemically-defined media and feeds and protocols allowing one to go from DNA to bioreactor harvest for the biological protein of interest. Pharma companies like - Pfizer and Lilly - have reported savings of 8-9 weeks during clone development and selection using similarly ZFN-engineered CHO-K1 cells altered at the GS locus.
See www.safcglobal.com/chozn for more technical and application information.
Posted by Bruce Lehr July 7th 2011.